Results 111 to 120 of about 98,309 (302)

Smoldering Systemic Mastocytosis Without Detectable KIT Mutation: A Debilitating Course and Therapeutic Challenge

open access: yesCancer Nexus, EarlyView.
Graphical abstract illustrating the clinical course and treatment response. ABSTRACT Systemic mastocytosis (SM) is a clonal hematologic neoplasm driven by activating KIT mutations, particularly D816V. Indolent SM typically follows a stable course, progression to higher‐burden subtypes is uncommon.
Homeniuk Anna   +5 more
wiley   +1 more source

Interaction study of CD20 and Rituximab’s scFv to propose an anti-CD20 CAR [PDF]

open access: yesAnnals of the V ISI, 2021
Alison Rebouças, Marcos Lourenzoni
openaire   +1 more source

STIM1 knock-down decreases the affinity of obinutuzumab for CD20 by altering CD20 localization to Triton-soluble membrane

open access: yes, 2020
Obinutuzumab is thought to exert its effects through its high antibody-dependent cellular cytotoxicity (ADCC) via glyco-engineering of the Fc region. In addition, obinutuzumab causes direct binding-induced cell death (DCD) only by specifically binding to
김주영
core   +1 more source

From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities

open access: yesCancer Nexus, EarlyView.
ABSTRACT Inflammatory bowel disease (IBD), primarily Crohn's disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract and an important risk factor for IBD‐associated cancer. Increasing evidence suggests that gut microbiota dysbiosis, epithelial barrier dysfunction, and immune microenvironment remodeling
Xue Zhang   +4 more
wiley   +1 more source

Cd20-negative diffuse large b-cell lymphoma subtype: a look at texas cancer registry

open access: yesHematology Reports, 2020
Introduction CD20-negative diffuse large B-cell lymphoma (DLBCL) histologic subtypes are rare and aggressive lymphomas. As these lymphomas are rare, most epidemiology and survival information is derived from case reports and case series.
Kartik Anand   +2 more
doaj  

Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment

open access: yes, 2013
Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of different haematological cancers with a wide range of aggressiveness. NHLs represent >80% of lymphomas and the majority of NHLs involve B cells.
Letizia Polito   +9 more
core  

Anti-CD20 mAbs-induced programed cell death.

open access: yes, 2014
Schematic diagram illustrating the kinetics of changes in CD20 expression followed 0.5Gy γ-radiation and sequence of events in the proposed possible cell death pathway evoked by type I anti-CD20 mAbs (Rtx) and type I anti-CD20 mAbs (Tst).
Vijay Singh (1439023)   +5 more
core   +1 more source

Comparison of Tissue Preparations to Identify and Phenotype T Cells in Human Colorectal Tumor Tissue

open access: yesCytometry Part A, EarlyView.
ABSTRACT Archived patient samples (e.g., formalin‐fixed paraffin embedded (FFPE) tissue blocks, cryoembedded tissue blocks, and frozen whole tissue samples) are a source of immune information for which corresponding patient data is often collected.
Justin F. Tirados   +5 more
wiley   +1 more source

CD20 [PDF]

open access: yesScience-Business eXchange, 2009
openaire   +2 more sources

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Home - About - Disclaimer - Privacy